What Sypharma does

Sypharma Pty Ltd is an Australian specialty contract development and manufacturing organization (CDMO) founded in 2005 and headquartered in Dandenong, Victoria. The company delivers integrated pharmaceutical development and manufacturing services to innovative biotech developers, supporting clients from early-stage formulation and analytical development through scale-up, process validation, and commercial launch across a range of dosage forms.

Sypharma's core capabilities span aseptic fill-and-finish, terminal sterilization, single-use manufacturing for clinical trial injectables, intravenous fluid manufacturing, and non-sterile GMP excipient manufacturing (powder, liquid, and cream filling). Underlying technology is anchored by single-use manufacturing platforms that reduce contamination risk and enable rapid changeovers, complemented by in-house Chemistry and Microbiology quality-control laboratories that compress testing turnaround. The facility operates under cGMP with TGA, FDA, ISO 13485, and APVMA accreditations, allowing Sypharma to supply Australia and export markets. A separate Sykes Vet International sub-brand addresses veterinary pharmaceutical manufacturing under APVMA oversight.

The business model is B2B contract manufacturing: services are scoped and priced per engagement, with no publicly disclosed pricing. Revenue streams include full-service CDMO engagements, aseptic fill-and-finish, terminal sterilization, custom buffer and CIP solutions, IV fluid manufacturing, and non-sterile manufacturing. The company is privately held, founder/independently owned, with no disclosed institutional investors or funding rounds. Go-to-market is direct enterprise sales targeting biotech and vaccine developers, exemplified by long-standing partnerships with Vaxine Pty Ltd and the University of Queensland for COVID-19 vaccine candidates, a manufacturing collaboration with SCHOTT, and participation in the 2021 Genetis vaccine hub with Technovalia and BioNet.

Name

Sypharma

Legal name

Sypharma Pty Ltd

Website

https://sypharma.com.au

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Sypharma is an Australian specialty CDMO providing aseptic fill-and-finish, terminal sterilization, IV fluid, and single-use manufacturing services to innovative biotech developers across global regulated markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Contract pharmaceutical manufacturing
• Aseptic fill finish
• Biopharmaceutical CDMO services
• Vaccine manufacturing services
• Intravenous fluid production

Headquarters

HQ city

Dandenong

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Full-service CDMO providing integrated services including new drug development, early stage formulation, analytical development, scale-up, process validation, and commercial manufacturing for various dosage forms.
2. Aseptic Fill & Finish: Manufacturing services for aseptic filling of pharmaceutical products including clinical trial injectables and commercial supplies.
3. Terminal Sterilization: Terminal sterilization manufacturing services for pharmaceutical products requiring this production method.
4. Custom Buffer & CIP Solutions: Custom formulation and cleaning solutions for pharmaceutical manufacturing.
5. IV Fluid Manufacturing: Precision manufacturing of intravenous fluids for clinical and commercial use.
6. Non-Sterile Manufacturing: GMP-grade excipient manufacturing for pharmaceutical and biopharmaceutical formulation, including powder, liquid and cream filling lines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Sypharma is an Australian specialty contract development and manufacturing organization (CDMO) providing integrated pharmaceutical development and manufacturing services. Its core offerings include aseptic fill and finish, terminal sterilization, single-use manufacturing for clinical injectables, GMP intravenous (IV) fluid manufacturing, non-sterile excipient manufacturing, and custom buffer and CIP solutions, delivered to innovative biotech and vaccine developers across global markets.

Product overview

Sypharma is an Australian speciality contract development manufacturing organization (CDMO) offering integrated pharmaceutical development and manufacturing services. The portfolio includes core manufacturing services (Aseptic Fill & Finish, Terminal Sterilization, Single Use Manufacturing, Intravenous Fluid Manufacturing, Non-Sterile Manufacture), custom formulation solutions (Custom Buffer & CIP Solutions), veterinary products (Sykes Vet International), and in-house quality control laboratories. These services span the full drug development lifecycle from discovery through commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• Sykes Vet International: Veterinary pharmaceutical manufacturing services offered by Sypharma.

Products and services

• Aseptic Fill & Finish Sterile aseptic filling and finishing services for pharmaceutical products, including clinical trial injectables and commercial supplies, conducted under cGMP conditions for biotech and pharmaceutical clients.
• Terminal Sterilization Terminal sterilization manufacturing services for pharmaceutical products that require terminal sterilization as part of their production method, ensuring product safety and regulatory compliance.
• Custom Buffer & CIP Solutions Custom formulation of buffer solutions and clean-in-place (CIP) solutions to support pharmaceutical manufacturing operations for client manufacturing processes.
• Sykes Vet International Veterinary pharmaceutical manufacturing services operated under the Sykes Vet International sub-brand, covering GMP manufacturing of veterinary medicines and related products.
• Single-Use Manufacturing Single-use manufacturing solutions for clinical trial injectables, offering flexible, contamination-free GMP production with reduced changeover time, lower contamination risk, cost savings, and faster time to market.
• Intravenous Fluid Manufacturing GMP manufacture of intravenous (IV) fluids for clinical and commercial use, delivered via automated systems to ensure precision, sterility, and quality at scale for pharmaceutical clients.
• Non-Sterile Manufacture GMP-grade non-sterile excipient manufacturing supporting pharmaceutical and biopharmaceutical formulation, with powder, liquid, and cream filling lines delivering consistent quality and regulatory compliance.

Quantifiable outcome

• 8 million doses of SpikoGen vaccine safely delivered

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Vaxine Pty LtdcoreStrategic or Co-development Partner · 30 June 2020Partnership for manufacture of COVAX-19 and SpikoGen COVID-19 vaccines. Sypharma performed fill and finish of Vaxine's recombinant spike protein vaccine and manufactured Advax adjuvant products. First Australian-developed Covid-19 vaccine to enter human trials.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Lonza: World's largest CDMO with broad aseptic fill-finish, mammalian and microbial biologics, and sterile manufacturing capabilities — competing with Sypharma for biotech and vaccine programs but at vastly larger scale.
• PCI Pharma Services: Global CDMO with sterile fill-finish, clinical and commercial manufacturing, and packaging services — competing for similar biotech clients at larger scale.
• Siegfried Holding: Swiss CDMO with aseptic fill-finish, terminal sterilization and API manufacturing — offers overlapping capabilities with Sypharma's sterile small-molecule drug product services.
• Catalent: Large global CDMO offering aseptic fill-finish, sterile manufacturing and integrated development across biologics and small molecules — operates at significantly greater scale and geographic reach than Sypharma.
• Recipharm: European CDMO with sterile fill-finish, biopharmaceuticals and vaccine manufacturing — comparable service portfolio with much larger international footprint.
• Aenova Group: German-based CDMO with solid, semi-solid and sterile injectable manufacturing capabilities — overlaps with Sypharma's small-molecule drug product and aseptic fill-finish offerings.
• Thermo Fisher Scientific (Patheon CDMO): Operates the Patheon CDMO network offering aseptic fill-finish, biologics and small-molecule drug product services — a broad incumbent competing with Sypharma for global biotech manufacturing programs.

Direct peers

• Hovione: Portugal-headquartered specialty CDMO with strong aseptic fill-finish, terminal sterilization and integrated drug development services — directly comparable to Sypharma's core service mix across small-molecule and biologic injectables.
• IDT Biologika: German CDMO specializing in vaccines, biotech and aseptic fill-finish — comparable to Sypharma on vaccine/biologics focus, cGMP manufacturing and pandemic-response capabilities.
• Luina Bio: Australian cGMP CDMO offering biologics manufacturing, aseptic fill-finish and vaccine development — the closest domestic peer to Sypharma in scale, capability set and regulatory positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sypharma